AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12953347
Drug: CHF 3381
RxNorm normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF 3381 (25, 50, 100, 200, 300, 450, and 600 mg)
Trial: 12953347
Drug: CHF 3381
RxNorm normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF 3381 (600 mg)
Trial: 12953347
Drug: CHF 3381
RxNorm normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF 3381 (various doses)
Trial: 12953347
Drug: CHF 3381
RxNorm normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF 3381 (300 and 600 mg)
Trial: 12953347
Drug: CHF 3381
RxNorm normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF 3381 (200 mg)
Trial: 12953347
Drug: CHF 3381
RxNorm normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF 3381 (300 mg)
Trial: 10962546
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate (20 mg daily subcutaneous injection)
Trial: 8722342
Drug: Busulfan 16
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan 16 mg/kg and cyclophosphamide 120 mg/kg (BuCy2) preparative regimen
Trial: 3901832
Drug: 12-hour theophylline
RxNorm normalized name: 12 HR theophylline 350 MG Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-hour theophylline preparation (Theo-Dur)
Trial: 3901832
Drug: 24-hour theophylline
RxNorm normalized name: 24 HR theophylline 150 MG Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour theophylline preparation (Theo-24)
Trial: 29381569
Drug: Lidocaine infusion
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine infusion therapy (3 mg/kg) administered once a week for 4 consecutive weeks
Trial: 29381569
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusions (control group) administered once a week for 4 consecutive weeks
Trial: 25699349
Drug: Voluven 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voluven 7 ml/kg in 20 mins before induction and 8 ml/kg after induction
Trial: 25699349
Drug: Plasmalyte A
RxNorm normalized name: PLASMALYTE A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmalyte A 6 ml/kg/h
Trial: 22856218
Drug: Hyperbaric solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric solution (7.5 mg levobupivacaine + 50 microg Fentanyl + 1 ml 10% glucose)
Trial: 22856218
Drug: Hypobaric solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypobaric solution (7.5 mg levobupivacaine + 50 microg Fentanyl + 1 ml 0.9% NaCl)
Trial: 3277875
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 vaginal suppositories
Trial: 18019402
Drug: Valacyclovir at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir at 14.3 mg/kg every 6 hours
Trial: 16615261
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion (intervention group)
Trial: 16615261
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (prior to insulin infusion)
Trial: 14669937
Drug: 7.75% carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.75% carbohydrate solution
Trial: 14669937
Drug: 7.75% carbohydrate/1.94%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.75% carbohydrate/1.94% protein solution
Trial: 10947748
Drug: Rapacuronium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapacuronium 1.5 mg x kg(‐1) with neostigmine
Trial: 10947748
Drug: Rapacuronium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapacuronium 1.5 mg x kg(‐1) without neostigmine
Trial: 10947748
Drug: Succinylcholine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 1.0 mg x kg(‐1)
Trial: 10947748
Drug: Rapacuronium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapacuronium 1.5 mg x kg(‐1)
Trial: 8773908
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not explicitly defined, but implied as no treatment or different duration)
Trial: 8773908
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with interferon
Trial: 1537998
Drug: Accelerated rt‐PA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated rt‐PA (1.25 mg/kg over 90 min, regimen C)
Trial: 1537998
Drug: Exaggerated (60‐min)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exaggerated (60‐min) dosage regimen
Trial: 1537998
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (accelerated rt‐PA and intravenous urokinase, regimen E)
Trial: 1537998
Drug: Conventional 3‐h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional 3‐h dosing regimens
Trial: 29061222
Drug: Improvisational music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improvisational music therapy (IMT) - high-frequency sessions (3 sessions per week)
Trial: 29061222
Drug: Improvisational music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improvisational music therapy (IMT) - low-frequency sessions (1 session per week)
Trial: 29061222
Drug: Improvisational music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improvisational music therapy (IMT)
Trial: 25822648
Drug: Allogeneic bone
RxNorm normalized name: Human allogeneic bone marrow derived osteoblastic cells
DrugBank: Human allogeneic bone marrow derived osteoblastic cells (DB17890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic bone marrow MSCs (40 × 10^6 cells, intra-articular injection)
Trial: 25822648
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (60 mg, single dose, intra-articular)
Trial: 15288592
Drug: pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pravastatin 40 mg/day plus piperazine-sultosilate 1000 mg/day
Trial: 25148829
Drug: pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pravastatin 40 mg/day
Trial: 8202005
Drug: Single-dose prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose prednisolone
Trial: 3479045
Drug: Cefotetan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan (2 g) administered at 12-hour intervals
Trial: 3479045
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered at 12-hour intervals
Trial: 22647321
Drug: Multidisciplinary rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary rehabilitation treatment (MRT)
Trial: 26581842
Drug: Atorvastatin (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (oral 20 mg/night for 8 weeks)
Trial: 23738908
Drug: 3 mL
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL of EMLA cream (5% lidocaine 25 mg‐prilocaine 25 mg/g)
Trial: 23738908
Drug: 3 mL
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL of ultrasound gel (placebo)
Trial: 20684147
Drug: Two-compound ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-compound ointment (calcipotriene 50 microg/g and betamethasone 0.5 mg/g)
Trial: 20684147
Drug: Two-compound ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-compound ointment (calcipotriene 50 microg/g and betamethasone 0.5 mg/g) for 52 weeks
Trial: 20684147
Drug: Two-compound ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-compound ointment alternating with calcipotriene four-weekly
Trial: 20684147
Drug: Betamethasone 0.5
RxNorm normalized name: betamethasone 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone 0.5 mg/g (as dipropionate; Diprosone) ointment
Trial: 12923616
Drug: Sufentanil (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (initial bolus 0.5 micro g/kg and continuous infusion rate of 0.5 micro g/kg per hour)
Trial: 12923616
Drug: Midazolam (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (initial bolus 0.08 mg/kg and continuous infusion 0.05 mg/kg per hour)
Trial: 10875787
Drug: Oral BCG
RxNorm normalized name: Tice BCG Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral BCG vaccination (double-dose)
Trial: 10875787
Drug: Intradermal BCG
RxNorm normalized name: Tice BCG Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal BCG booster vaccination
Trial: 10875787
Drug: Oral BCG
RxNorm normalized name: Tice BCG Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral BCG vaccination
Trial: 28384828
Drug: Hydrocortisone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (0.5 mg/kg twice per day for 7 days, followed by 0.5 mg/kg per day for 3 days)
Trial: 25117853
Drug: Vigabatrin 1
RxNorm normalized name: vigabatrin 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin 1 g/day
Trial: 25117853
Drug: Vigabatrin 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin 6 g/day
Trial: 23835026
Drug: Intra-arterial thrombolysis
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial thrombolysis (IAT) after intravenous thrombolysis (IVT)
Trial: 21993064
Drug: Chlorhexidine mouthrinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine mouthrinse (10 ml of 0.2%)
Trial: 21993064
Drug: Cacao bean
RxNorm normalized name: Cacao bean
DrugBank: Cocoa (DB10977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cacao bean husk extract mouthrinse (10 ml of 0.1%)
Trial: 18785254
Drug: Atrasentan 10
RxNorm normalized name: ATRASENTAN
DrugBank: Atrasentan (DB06199)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrasentan 10 mg daily
Trial: 16541325
Drug: Cyclophosphamide, methotrexate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide, methotrexate, fluoracil (CMF) chemotherapy
Trial: 12925248
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg twice a day for 72 hours
Trial: 12925248
Drug: Dexamethasone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (20 to 80 mg intravenously during surgery)
Trial: 6150902
Drug: prenalterol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prenalterol (1 mg/60 min)
Trial: 6150902
Drug: prenalterol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prenalterol (2 mg/60 min)
Trial: 27842163
Drug: Anti-VEGF therapy
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-VEGF therapy (Bevacizumab and Ranibizumab) administered monthly for 6 months
Trial: 16645969
Drug: Budesonide 9
RxNorm normalized name: budesonide 9 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 9 mg/day
Trial: 12160813
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL lignocaine 2% with sodium hyaluronidase 150 IU/mL
Trial: 12160813
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL plain lignocaine 2%
Trial: 29693796
Drug: Cabozantinib 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 30 mg/m2/day
Trial: 29693796
Drug: Cabozantinib 40
RxNorm normalized name: cabozantinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 40 mg/m2/day
Trial: 29693796
Drug: Cabozantinib 55
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 55 mg/m2/day
Trial: 29693796
Drug: Cabozantinib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (all dose levels)
Trial: 26916566
Drug: Siponimod 4
RxNorm normalized name: SIPONIMOD
DrugBank: Siponimod (DB12371)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Siponimod 4 mg after 192 hours of discontinuation
Trial: 26916566
Drug: Siponimod (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siponimod (various doses) after up to 96 hours of discontinuation
Trial: 26916566
Drug: Siponimod (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siponimod (various doses)
Trial: 25594427
Drug: CT327 (TrkA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT327 (TrkA inhibitor)
Trial: 23099100
Drug: Computerized decision
RxNorm normalized name: Precise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized decision support tools in the EHR with direct-to-parent support (telephone coaching and twice-weekly text messages)
Trial: 8677865
Drug: Beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker therapy (n = 911; 33%)
Trial: 8677865
Drug: No beta-blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No beta-blocker therapy (n = 1,812; 67%)
Trial: 1355798
Drug: CVD 103-HgR
RxNorm normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 103-HgR vaccine (5 x 10(6), 5 x 10(7), 5 x 10(8), 5 x 10(9), or 1 x 10(10) CFU)
Trial: 1355798
Drug: CVD 103-HgR
RxNorm normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 103-HgR vaccine (5 x 10(8) CFU)
Trial: 1355798
Drug: CVD 103-HgR
RxNorm normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 103-HgR vaccine (5 x 10(9) CFU)
Trial: 29742655
Drug: Gabapentin (1,200-3,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (1,200-3,000 mg/d)
Trial: 24152706
Drug: Creatine (Cr)
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Creatine (Cr) loading (5 g of Cr + 10 g of fructose, four times daily for 5 days)
Trial: 24152706
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 g of fructose, four times daily for 5 days)
Trial: 23155026
Drug: Heavier hens
RxNorm normalized name: Bartonella henselae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavier hens (1,733 g)
Trial: 23155026
Drug: Lighter hens
RxNorm normalized name: Bartonella henselae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lighter hens (1,606 g)
Trial: 20538329
Drug: Diluent inhalation
RxNorm normalized name: DILUENT
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diluent inhalation
Trial: 16259830
Drug: Current users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current users of hormone replacement therapy (HRT)
Trial: 16259830
Drug: Non-users of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-users of hormone replacement therapy (HRT)
Trial: 8681495
Drug: Albendazole (440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (440 mg/two times per day for 7 days)
Trial: 8681495
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg/two times per day for 7 days) plus metronidazole (250 mg/three times per day for 7 days)
Trial: 30982748
Drug: Hydrogen-rich water
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogen-rich water (HRW) 1 L per day for 28 days
Trial: 21878535
Drug: Letrozole +
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole + AS1402 (9 mg/kg weekly infusion)
Trial: 21878535
Drug: Letrozole only
RxNorm normalized name: Letrozole only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole only (2.5 mg daily)
Trial: 17950094
Drug: Miglitol 150
RxNorm normalized name: Miglitol
DrugBank: Miglitol (DB00491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miglitol 150 mg/d
Trial: 17950094
Drug: Mitiglinide 30
RxNorm normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mitiglinide 30 mg/d
Trial: 11332926
Drug: Zinc (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc (20 mg elemental)
Trial: 9110923
Drug: Bezafibrate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate (400 mg once daily)
Trial: 9110923
Drug: Micronised fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronised fenofibrate (200 mg once daily)
Trial: 28202033
Drug: Stepwise lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepwise lactate kinetics-oriented hemodynamic therapy
Trial: 28202033
Drug: ScvO2-oriented hemodynamic
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ScvO2-oriented hemodynamic therapy
Trial: 26387028
Drug: Loading-dose rosuvastatin
RxNorm normalized name: omadacycline 7-Day Oral Pack incuding loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading-dose rosuvastatin 20 mg 12 hours prior to PCI, with a second dose just before PCI.
Trial: 26387028
Drug: Loading-dose rosuvastatin
RxNorm normalized name: omadacycline 7-Day Oral Pack incuding loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading-dose rosuvastatin therapy.
Trial: 23288870
Drug: Simvastatin/ezetimibe 10/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin/ezetimibe 10/10 mg
Trial: 21627526
Drug: Vaccine B
RxNorm normalized name: meningococcal vaccine B and C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine B (2 mL doses, n = 12)
Trial: 21627526
Drug: Vaccine A
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine A (5 mL doses, n = 13)
Trial: 21627526
Drug: Sham vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham vaccine (n = 14)
Trial: 17225048
Drug: Groups A,
RxNorm normalized name: Meningococcal Polysaccharide Vaccine, Groups A, C Combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Groups A, B, C (iodine dose 450-600 mg/kg, injection duration 30 s)
Trial: 17225048
Drug: Group D
RxNorm normalized name: Prostaglandin group D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D (iodine dose 450 mg/kg, injection duration 25 s)
Trial: 15321810
Drug: High-soy diet
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-soy diet (104 +/- 24 mg total isoflavones/d)
Trial: 15321810
Drug: Low-soy diet
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-soy diet (0.54 +/- 0.58 mg total isoflavones/d)
Trial: 3364822
Drug: Epinephrine 1
RxNorm normalized name: epinephrine 1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine 1 mg
Trial: 9512230
Drug: Intracytoplasmic sperm
RxNorm normalized name: herring sperm DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracytoplasmic sperm injection (ICSI) in patients with previous failed fertilization or low fertilization rate
Trial: 9512230
Drug: Intracytoplasmic sperm
RxNorm normalized name: herring sperm DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracytoplasmic sperm injection (ICSI) in patients with primary male factor
Trial: 7518728
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment for 4 months in males
Trial: 7518728
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment for 4 months in females
Trial: 3177228
Drug: Diltiazem (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (120 to 180 mg twice daily, mean dose 307 mg/day)
Trial: 26887576
Drug: Aqua-cycling (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqua-cycling (two 45-min sessions weekly for 12 weeks)
Trial: 26259989
Drug: Ustekinumab half-standard
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ustekinumab half-standard dosing (HSD)
Trial: 26259989
Drug: Ustekinumab standard
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ustekinumab standard dosing (SD)
Trial: 21178616
Drug: Conventional-dose therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose therapy (including bortezomib and immune-modulatory drugs)
Trial: 19032132
Drug: Oxycodone PR/Naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone PR/Naloxone PR
Trial: 18708300
Drug: Oxycodone PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone PR
Trial: 17220048
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of losartan (100 mg)
Trial: 17220048
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of losartan (100 mg)